Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2020

01-02-2020 | Heparin

Factors associated with women’s adherence to postpartum thromboprophylaxis

Authors: Amihai Rottenstreich, Adi Karlin, Yosef Kalish, Gabriel Levin, Misgav Rottenstreich

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2020

Login to get access

Abstract

Postpartum low-molecular-weight heparin (LMWH) thromboprophylaxis is indicated for a substantial proportion of women. We assessed women’s adherence to postpartum thromboprophylaxis and the factors associated with adherence. This retrospective cohort study was conducted at a university hospital during 2018. Parturients for whom a recommendation for LMWH prophylaxis was given at discharge from the maternity ward were contacted at the end of the recommended post-discharge course of LMWH, and were invited to participate in a telephone survey. The main outcome measures were optimal (> 80%) and suboptimal adherence (< 80%) to LMWH administration, reasons for nonadherence, and views regarding LMWH, as assessed by an adapted Beliefs about Medication Questionnaire. Overall, 250 women completed the questionnaire. The median recommended duration of post-discharge LMWH was 7 [5–8] days. Suboptimal adherence was reported by 82 (32.8%); 45 (18.0%) women did not administer any LMWH dose following discharge and only 147 (58.8%) completed the full LMWH course. In multivariate analysis, patients’ perceptions of the necessity of LMWH [odds ratio (95% CI): 3.50 (2.12, 9.53), P = 0.002] and of the adequacy of the explanation given prior to discharge regarding LMWH technical administration [odds ratio (95% CI): 5.0 (2.33, 11.11), P < 0.001] were positively associated with optimal adherence. Nearly one-third of women prescribed postpartum LMWH thromboprophylaxis reported suboptimal adherence. Patients’ perceptions of the necessity of the treatment and their opinion of the adequacy of explanation regarding LMWH technical administration were identified as predictors of treatment compliance, and thus represent potential areas for improvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Berg CJ, Callaghan WM, Syverson C, Henderson Z (2010) Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 116:1302–1309CrossRef Berg CJ, Callaghan WM, Syverson C, Henderson Z (2010) Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 116:1302–1309CrossRef
2.
go back to reference Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143:697–706CrossRef Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143:697–706CrossRef
3.
go back to reference Jacobsen AF, Skjeldestad FE, Sandset PM (2008) Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 6:905–912CrossRef Jacobsen AF, Skjeldestad FE, Sandset PM (2008) Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 6:905–912CrossRef
4.
go back to reference Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736SCrossRef Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO et al (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e691S–e736SCrossRef
5.
go back to reference ACOG (2018) Practice bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol 132(1):e1–e17CrossRef ACOG (2018) Practice bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol 132(1):e1–e17CrossRef
7.
go back to reference Chan WS, Rey E, Kent N, Society of Obstetricians & Gynaecologists of Canada (2014) Clinical practice guideline #308: venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 36:527–553CrossRef Chan WS, Rey E, Kent N, Society of Obstetricians & Gynaecologists of Canada (2014) Clinical practice guideline #308: venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 36:527–553CrossRef
8.
go back to reference Cutler DM, Everett W (2010) Thinking outside the pillbox—medication adherence as a priority for healthcare reform. N Engl J Med 362:1553–1555CrossRef Cutler DM, Everett W (2010) Thinking outside the pillbox—medication adherence as a priority for healthcare reform. N Engl J Med 362:1553–1555CrossRef
9.
go back to reference Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO), December 2005 Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO), December 2005
10.
go back to reference Sanz E, Gomez-Lopez T, Martinez-Quintas MJ (2001) Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 95:127–131CrossRef Sanz E, Gomez-Lopez T, Martinez-Quintas MJ (2001) Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 95:127–131CrossRef
11.
go back to reference Nordeng H, Ystrom E, Einarson A (2010) Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 66:207–214CrossRef Nordeng H, Ystrom E, Einarson A (2010) Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 66:207–214CrossRef
12.
go back to reference Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A (2005) Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counselling and determinants of decision making. Arch Womens Ment Health 8:214–220CrossRef Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A (2005) Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counselling and determinants of decision making. Arch Womens Ment Health 8:214–220CrossRef
14.
go back to reference Hordern CE, Bircher CW, Prosser-Snelling EC, Fraser FK, Smith RP (2015) Patient compliance with postnatal thromboprophylaxis: an observational study. J Obstet Gynaecol 35(8):793–796CrossRef Hordern CE, Bircher CW, Prosser-Snelling EC, Fraser FK, Smith RP (2015) Patient compliance with postnatal thromboprophylaxis: an observational study. J Obstet Gynaecol 35(8):793–796CrossRef
15.
go back to reference Patel JP, Auyeung V, Patel RK, Marsh MS, Green B, Arya R et al (2012) Women’s views on and adherence to low-molecular-weight heparin therapy during pregnancy and the puerperium. J Thromb Haemost 10(12):2526–2534CrossRef Patel JP, Auyeung V, Patel RK, Marsh MS, Green B, Arya R et al (2012) Women’s views on and adherence to low-molecular-weight heparin therapy during pregnancy and the puerperium. J Thromb Haemost 10(12):2526–2534CrossRef
16.
go back to reference Guimicheva B, Patel JP, Roberts LN, Subramanian D, Arya R (2019) Women’s views, adherence and experience with postnatal thromboprophylaxis. Thromb Res 173:85–90CrossRef Guimicheva B, Patel JP, Roberts LN, Subramanian D, Arya R (2019) Women’s views, adherence and experience with postnatal thromboprophylaxis. Thromb Res 173:85–90CrossRef
17.
go back to reference Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24CrossRef Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24CrossRef
18.
go back to reference Clifford S, Barber N, Elliott R, Hartley E, Horne R (2006) Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 28:165–170CrossRef Clifford S, Barber N, Elliott R, Hartley E, Horne R (2006) Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 28:165–170CrossRef
19.
go back to reference Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464–470CrossRef Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program 2013:464–470CrossRef
20.
go back to reference Chan NC, Eikelboom JW, Weitz JI (2016) Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ Res 118(9):1409–1424CrossRef Chan NC, Eikelboom JW, Weitz JI (2016) Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ Res 118(9):1409–1424CrossRef
21.
go back to reference Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R (2016) Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 14(8):1673–1676CrossRef Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R (2016) Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 14(8):1673–1676CrossRef
22.
go back to reference Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G (2016) The direct factor Xa inhibitor rivaroxaban passes into human breast milk. Chest 150(1):e1–e4CrossRef Wiesen MH, Blaich C, Müller C, Streichert T, Pfister R, Michels G (2016) The direct factor Xa inhibitor rivaroxaban passes into human breast milk. Chest 150(1):e1–e4CrossRef
24.
go back to reference Zhao Y, Ding A, Arya R, Patel JP (2018) Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study. Int J Clin Pharm 40(6):1511–1518CrossRef Zhao Y, Ding A, Arya R, Patel JP (2018) Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study. Int J Clin Pharm 40(6):1511–1518CrossRef
25.
go back to reference Greer IA, Hunt BJ (2005) Low molecular weight heparin in pregnancy: current issues. Br J Haematol 128:593–601CrossRef Greer IA, Hunt BJ (2005) Low molecular weight heparin in pregnancy: current issues. Br J Haematol 128:593–601CrossRef
26.
go back to reference Revell BJ, Smith RP (2010) Thrombosis and embolism in pregnancy and the puerperium, reducing the risk: what proportion of patients reach the threshold for thromboprophylaxis? Obstet Med 4:12–14CrossRef Revell BJ, Smith RP (2010) Thrombosis and embolism in pregnancy and the puerperium, reducing the risk: what proportion of patients reach the threshold for thromboprophylaxis? Obstet Med 4:12–14CrossRef
27.
go back to reference Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, Watters JM, Schreiber MA (2014) Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg 149(4):365–370CrossRef Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, Watters JM, Schreiber MA (2014) Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. JAMA Surg 149(4):365–370CrossRef
Metadata
Title
Factors associated with women’s adherence to postpartum thromboprophylaxis
Authors
Amihai Rottenstreich
Adi Karlin
Yosef Kalish
Gabriel Levin
Misgav Rottenstreich
Publication date
01-02-2020
Publisher
Springer US
Keyword
Heparin
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2020
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01952-4

Other articles of this Issue 2/2020

Journal of Thrombosis and Thrombolysis 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine